Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin's Lymphoma (BMT CTN 0401).

Trial Profile

Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin's Lymphoma (BMT CTN 0401).

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2016 Time frame for primary endpoint changed from 2-3 years to 1-2 years.
    • 04 May 2016 Time frame for primary endpoint changed from 2-3 years to 1-2 years.
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top